198 related articles for article (PubMed ID: 29449534)
1. TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.
Liang C; Wang S; Qin C; Bao M; Cheng G; Liu B; Shao P; Lv Q; Song N; Hua L; Gu M; Li J; Wang Z
Cell Death Dis; 2018 Feb; 9(2):155. PubMed ID: 29449534
[TBL] [Abstract][Full Text] [Related]
2. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
4. Androgen-responsive tripartite motif 36 enhances tumor-suppressive effect by regulating apoptosis-related pathway in prostate cancer.
Kimura N; Yamada Y; Takayama KI; Fujimura T; Takahashi S; Kume H; Inoue S
Cancer Sci; 2018 Dec; 109(12):3840-3852. PubMed ID: 30238687
[TBL] [Abstract][Full Text] [Related]
5. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
Sen A; O'Malley K; Wang Z; Raj GV; Defranco DB; Hammes SR
J Biol Chem; 2010 Sep; 285(37):28787-95. PubMed ID: 20628053
[TBL] [Abstract][Full Text] [Related]
6. Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.
Coutinho-Camillo CM; Salaorni S; Sarkis AS; Nagai MA
Cancer Genet Cytogenet; 2006 Apr; 166(2):130-8. PubMed ID: 16631469
[TBL] [Abstract][Full Text] [Related]
7. Physalins A and B inhibit androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression.
Han H; Qiu L; Wang X; Qiu F; Wong Y; Yao X
Biol Pharm Bull; 2011; 34(10):1584-8. PubMed ID: 21963499
[TBL] [Abstract][Full Text] [Related]
8. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
9. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
10. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells.
Gravina GL; Festuccia C; Angelucci A; Poletti A; Capuano D; Vicentini C; Motta M; Bologna M
Int J Oncol; 2004 Jul; 25(1):97-104. PubMed ID: 15201994
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.
Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407
[TBL] [Abstract][Full Text] [Related]
14. Independence of HIF1a and androgen signaling pathways in prostate cancer.
Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
[TBL] [Abstract][Full Text] [Related]
15.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
16. UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
Gao Y; Liu Y; Liu Y; Peng Y; Yuan B; Fu Y; Qi X; Zhu Q; Cao T; Zhang S; Yin L; Li X
Cancer Lett; 2021 Nov; 520():172-183. PubMed ID: 34265399
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
18. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
20. Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells.
Munkley J; Lafferty NP; Kalna G; Robson CN; Leung HY; Rajan P; Elliott DJ
BMC Cancer; 2015 Jan; 15():9. PubMed ID: 25592066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
